Singapore-based ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company with a focus on immunology, working towards developing treatments that have the potential to significantly change the lives of patients. At present, ASLAN004, a monoclonal antibody aimed at treating atopic dermatitis and other immunology indications by targeting the IL-13 receptor a1 subunit, and ASLAN003, a small-molecule inhibitor developed to assist in treating autoimmune diseases, constitute the company's clinical portfolio. Additionally, the company has partnered with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. for a joint venture to explore immuno-oncology therapeutics targeting the AhR pathway in various global markets. ASLAN's partners include Almirall, Array BioPharma, and CSL Limited. The company came into being in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals Limited's ticker is ASLN
The company's shares trade on the NASDAQ stock exchange
They are based in Singapore, Singapore
There are 51-200 employees working at ASLAN Pharmaceuticals Limited
It is http://aslanpharma.com/
ASLAN Pharmaceuticals Limited is in the Healthcare sector
ASLAN Pharmaceuticals Limited is in the Biotechnology industry
The following five companies are ASLAN Pharmaceuticals Limited's industry peers: